HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ:ALDX) and maintained a $15 price target.
June 16, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Matthew Caufield reiterated a Buy rating on Aldeyra Therapeutics and maintained a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by HC Wainwright & Co. analyst Matthew Caufield indicates a positive outlook for Aldeyra Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100